Literature DB >> 20092592

Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery.

Ghasem Fakhraie1, Joao F Lopes, George L Spaeth, Juliana Almodin, Parul Ichhpujani, Marlene R Moster.   

Abstract

PURPOSE: To determine if postoperative topical cyclosporine 0.05% has any beneficial effect following trabeculectomy.
METHODS: This was an interventional, randomized, prospective, double-masked clinical trial of 44 consecutive patients with uncontrolled glaucoma requiring filtration surgery. Ocular surface disease index questionnaire and comprehensive ocular exam, including Schirmer's tear test 1, were performed. Patients underwent routine trabeculectomy, with or without phacoemulsification. The study group (n = 22) received cyclosporine 0.05%, and the control group (n = 22) received artificial tears. Patients were evaluated at 1 and 6 months post surgery. Outcome measures were intraocular pressure, success rate, bleb appearance, ocular surface disease index, Schirmer's tear test 1 and conjunctival inflammation.
RESULTS: Thirty-nine patients completed the study (19 in the study group, 20 in the control group). The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513). Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837). There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery. The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.
CONCLUSIONS: Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20092592     DOI: 10.1111/j.1442-9071.2009.02134.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  5 in total

1.  Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction.

Authors:  Ho-Yun Kim; Ji-Eun Lee; Ha-Na Oh; Ju-Whan Song; Sang-Youp Han; Jong-Soo Lee
Journal:  Int J Ophthalmol       Date:  2018-04-18       Impact factor: 1.779

Review 2.  The control of conjunctival fibrosis as a paradigm for the prevention of ocular fibrosis-related blindness. "Fibrosis has many friends".

Authors:  Peng Tee Khaw; Yann Bouremel; Stephen Brocchini; Christin Henein
Journal:  Eye (Lond)       Date:  2020-06-25       Impact factor: 3.775

3.  A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye.

Authors:  Yuli Park; Jong Suk Song; Chul Young Choi; Kyung Chul Yoon; Hyung Keun Lee; Hyun Seung Kim
Journal:  J Ocul Pharmacol Ther       Date:  2016-12-08       Impact factor: 2.671

4.  PLA-PEG Implant as a Drug Delivery System in Glaucoma Surgery: Experimental Study.

Authors:  Viktoriya N Germanova; Elena V Karlova; Larisa T Volova; Andrey V Zolotarev; Viktoriya V Rossinskaya; Ivan D Zakharov; Aleksandr R Korigodskiy; Violetta V Boltovskaya; Irina F Nefedova; Mariya V Radaykina
Journal:  Polymers (Basel)       Date:  2022-08-21       Impact factor: 4.967

5.  P-glycoprotein Blockers Augment the Effect of Mitomycin C on Human Tenon's Fibroblasts.

Authors:  Andrew J R White; Elizabeth Kelly; Paul R Healey; Jonathan G Crowston; Paul Mitchell; Hans Zoellner
Journal:  Transl Vis Sci Technol       Date:  2013-06-28       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.